Universal Ibogaine Inc. (IBO.V)

CAD 0.02

(0.0%)

Operating Expenses Summary of Universal Ibogaine Inc.

  • Universal Ibogaine Inc.'s latest annual operating expenses in 2022 was 5.81 Million CAD , up 50.51% from previous year.
  • Universal Ibogaine Inc.'s latest quarterly operating expenses in 2023 Q3 was 847.31 Thousand CAD , up 0.01% from previous quarter.
  • Universal Ibogaine Inc. reported a annual operating expenses of 3.86 Million CAD in annual operating expenses 2021, up 6423.67% from previous year.
  • Universal Ibogaine Inc. reported a annual operating expenses of 59.24 Thousand CAD in annual operating expenses 2020, down -13.95% from previous year.
  • Universal Ibogaine Inc. reported a quarterly operating expenses of 847.23 Thousand CAD for 2023 Q2, up 6.53% from previous quarter.
  • Universal Ibogaine Inc. reported a quarterly operating expenses of 795.29 Thousand CAD for 2023 Q1, down -33.9% from previous quarter.

Annual Operating Expenses Chart of Universal Ibogaine Inc. (2022 - 2018)

Historical Annual Operating Expenses of Universal Ibogaine Inc. (2022 - 2018)

Year Operating Expenses Operating Expenses Growth
2022 5.81 Million CAD 50.51%
2021 3.86 Million CAD 6423.67%
2020 59.24 Thousand CAD -13.95%
2019 68.85 Thousand CAD -60.93%
2018 176.22 Thousand CAD 0.0%

Peer Operating Expenses Comparison of Universal Ibogaine Inc.

Name Operating Expenses Operating Expenses Difference
Arch Biopartners Inc. 3.22 Million CAD -80.308%
Covalon Technologies Ltd. 14.36 Million CAD 59.496%
Hemostemix Inc. 2.15 Million CAD -169.714%
Kane Biotech Inc. 3.46 Million CAD -67.79%
MedMira Inc. 1.5 Million CAD -285.386%
Marvel Biosciences Corp. 2.31 Million CAD -150.85%
NervGen Pharma Corp. 17.77 Million CAD 67.277%
XORTX Therapeutics Inc. 6.38 Million CAD 8.85%